Pancreatic cancer

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

Retrieved on: 
Thursday, February 22, 2024
Neoplasm, Actinium-225, Cancer, Radionuclide, Therapy, Receptor (biochemistry), Patient, Clinical trial, Pancreatic cancer, PET

This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.

Key Points: 
  • This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.
  • Figure 1 below shows the before and after optimization of MNPR-101-Zr, Monopar’s radiopharmaceutical imaging agent for advanced solid tumors expressing uPAR.
  • Preclinical data to date demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes.
  • “We are aiming to present these promising preclinical results at an upcoming scientific meeting.”

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Retrieved on: 
Tuesday, February 20, 2024
Fast Track, FDA, City, Food, U.S. FDA, FACP, RAS, Therapy, PDAC, Patient, Oncology, MAPK, Pancreatic cancer, Cancer, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) who have failed one line of treatment. IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.

Key Points: 
  • IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.
  • “We welcome FDA’s decision to grant Fast Track designation for IMM-1-104.
  • Our Phase 1/2a study is designed to evaluate IMM-1-104 in pancreatic cancer, as well as a number of other tumor types associated with the RAS pathway.
  • City of Hope offers many clinical trials testing innovative treatments for people with pancreatic cancer," Chung said.

Team SAMBAI, TOUCH, The Black Breast Cancer Alliance, Named As Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024
Research, Women, Communications, African American, Health, Social Activism, Consumer, Science, Oncology, Breast cancer, Pancreatic Cancer Action, Incidence, Prostate Cancer UK, Survivor, BSN, Caregiver, Doctor of Philosophy, Prostate cancer, RN, MD, Education, Cancer Research UK, Prostate, National Cancer Institute, Breast, Safety, Organization, Patient, Ecosystem, Clinical trial, Factorization of polynomials, Team, Grand Challenges, Trust, Pancreatic cancer, Mortality, Morehouse School of Medicine, Cancer, Partnership, Pharmaceutical industry

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.
  • TOUCH, The Black Breast Cancer Alliance, as part of Team SAMBAI, is the first U.S.
  • Black-led breast cancer advocacy group to be an integral partner in the international Cancer Grand Challenge study.
  • Inequities in cancer prevention, screening, and treatment lead to disparities in cancer incidence and mortality and are a significant public health concern.

Corbin Advisors Adds Top Talent to Lead Healthcare Vertical

Retrieved on: 
Thursday, February 29, 2024
Professional Services, Communications, Other Professional Services, Finance, Consulting, Other Communications, Public Relations, Investor Relations, Hospital, Evercore, J. P. Morgan, Research fellow, Basketball, Culture, Pharmacy, Health care, SVB Securities, Organization, Policy, TCS, Pancreatic cancer, Institution, Research, Institutional Investor, Football, Pharmaceutical industry

Leveraging his experience on the sell side covering the healthcare sector and advising public companies, Mr. Newshel will oversee Corbin's Healthcare vertical, building on the firm's long-standing client relationships across the sector, including biotech, specialty and generic pharma, diagnostics, med tech, healthcare services, and IT.

Key Points: 
  • Leveraging his experience on the sell side covering the healthcare sector and advising public companies, Mr. Newshel will oversee Corbin's Healthcare vertical, building on the firm's long-standing client relationships across the sector, including biotech, specialty and generic pharma, diagnostics, med tech, healthcare services, and IT.
  • "Mike is a long-tenured, Institutional Investor -ranked healthcare expert who brings nearly two decades of sector experience to our specialized talent base at Corbin,” said Rebecca Corbin, Founder and CEO of Corbin Advisors .
  • “His extensive sell-side experience, deep equity market knowledge, and expertise across the broader healthcare ecosystem will create significant value for our healthcare clients.
  • In addition, he brings deep expertise on the U.S. healthcare system, specifically policy and regulation.

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Research, FDA, MTD, DDC, Ovarian cancer, Patient, Tax, Pancreatic cancer, IND, NUVB, Insurance, Cryptocurrency

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Nuvation Bio has completed the Phase 1 monotherapy study in advanced solid tumors and determined the MTD in patients.
  • As of December 31, 2023, Nuvation Bio had cash, cash equivalents and marketable securities of $611.2 million.
  • For the three months ended December 31, 2023, Nuvation Bio reported a net loss of $13.8 million, or $(0.06) per share.

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Mental Health, Health, Infectious Diseases, Neurology, Pharmaceutical, Biotechnology, NSCLC, TED, Blood pressure, Cervical cancer, Psoriasis, Cetuximab, Infection, New Drug Application, SCLC, MAA, National Medical Products Administration, PMA, CIDP, NTRK, FDA, Nivolumab, Food, GEJ, Shanda, Schizophrenia, PDUFA, CRC, Bristol Myers Squibb, BMS, ADP, Safety, Mirati, TPS, Disease, HKT, Patient, Clinical trial, METIS, Fusion, Pancreatic cancer, NDA, NMPA, Pharmaceutical industry

The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.

Key Points: 
  • The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.
  • Zai Lab has joined the global Phase 3 FORTITUDE-102 study of bemarituzumab in combination with nivolumab and chemotherapy in first-line gastric or GEJ cancer in Greater China.
  • Zai Lab to submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.
  • Zai Lab to complete patient enrollment in the China bridging study in schizophrenia in the fourth quarter of 2024.

Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham

Retrieved on: 
Wednesday, February 21, 2024
Commercial Building & Real Estate, Construction & Property, Technology, Consulting, Pharmaceutical, Oncology, Professional Services, Neurology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Health, Research, Senior, Culture, SCC, Epidermolysis bullosa, Pancreatic cancer, Sarcopenia, Cresa, Gold, Greater, Property, LEED, EB, Netherlands Architecture Institute, Lease administration, Knight Frank, Biology, Red Line (MBTA), Partnership, Therapy, Breast cancer, Multimedia, Capital market, Liver disease, Carcinoma, Type, Third, Lincoln, Quality of life, Government, GBM, Patient, Medicine, Glioblastoma, Business transaction management, Engineered wood

ft. of lab and office space at 300 Third Avenue in Waltham, Mass.

Key Points: 
  • ft. of lab and office space at 300 Third Avenue in Waltham, Mass.
  • View the full release here: https://www.businesswire.com/news/home/20240221278304/en/
    300 Third Avenue in Waltham, Massachusetts.
  • 300 Third Avenue is a 143,533-sq.-ft. purpose-built life science building with four stories of laboratory space and 441 on-site parking spaces.
  • Lincoln Property Company (“Lincoln”) is one of the largest diversified real estate services companies with 35 offices across the United States the United Kingdom and Europe.

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Retrieved on: 
Wednesday, February 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cancer, PFS, PD, KIT, Toxicity, Anemia, Roche, Research and development, Security (finance), Part, Hypoxia, PD-1, Belzutifan, Safety, Income tax, Death, Access code, Administration, Exelixis, Webcast, Patient, Acceleration, TIGIT, Plasma, G&A, Pancreatic cancer, AXL, CD73, Pharmaceutical industry

Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.

Key Points: 
  • Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.
  • The companies also plan to initiate a Phase 2 trial to evaluate domvanalimab plus zimberelimab in a new disease setting.
  • Arcus will host a conference call and webcast today, February 21, at 2:00 PM PT / 5:00 PM ET to discuss its fourth-quarter and full-year 2023 financial results and pipeline updates.
  • To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com .

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, March 7, 2024
Neoplasm, Research, Toxicity, SCCA, FOLFIRINOX, Trifluridine/tipiracil, PR, Society, Breast, Health, Poster, Immunotherapy, Anal cancer, Pancreatic cancer, Fast Track, Anal, Progression-free survival, SITC, Pelareorep, Annual general meeting, Congress, Cancer, Gastrointestinal cancer, AB, International, Cohort, ESMO, Conference, Safety, TILS, Tumor microenvironment, Clinical trial, Survival, MOA, Oncology, Colorectal cancer, TIL, Blood, FDA, TSX, Thought, Pancreatic Cancer Action Network, Anal canal, PDAC, Patient, ONC, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, March 7, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023.
  • General and administrative expenses for the fourth quarter of 2023 were $4.2 million, compared to $3.7 million for the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $4.7 million, compared to $4.8 million for the fourth quarter of 2022.
  • The net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $8.6 million for the fourth quarter of 2022.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Cancer, Cachexia, Toxicity, Anemia, Multimedia, Cell proliferation, NIH, Molecular biology, Pancreatic cancer, FDA, Quality of life, Animal, Drug development, Growth, Gallbladder, Metastasis, Nausea, Peripheral neuropathy, Argyreia nervosa, Lung, Breast, Stomach, Life expectancy, Leukemia, Patient, Paclitaxel, Survival, Diagnosis, Research, BGX, Biochemistry, Pharmaceutical industry

TAIPEI, March 6, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.